Comparable Effectiveness of Weight-Based and Fixed-Dose Pembrolizumab in Non–Small Cell Lung Cancer: Insights From a National Real-World Cohort | JCO Oncology Practice PURPOSEPembrolizumab, a PD-1 immune checkpoint inhibitor (ICI), is a standard first-line treatment for advanced non–small cell lung cancer (NSCLC). Although fixed-dose pembrolizumab (200 mg once every...

Protocolo a dosis fija de pembrolizumab es comparable al basado en el peso en pac c/CA pulmón no microcítico, protocolo basado en el peso puede ser coste-efectiva en pacientes c/peso bajo y en situaciones con recursos limitado #pembrolizumab #dosification ascopubs.org/doi/abs/10.1...